证券代码：600998 证券简称：九州通 公告编号：临 2025-075 九州通医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 4 日 （星期二） 13:00-14:00 会议召开地点：上海证券交易所上证路演中心（https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 问题征集：投资者可于 2025 年 10 月 28 日 （星期二） 至 11 月 3 日 （星期一） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jztdmc@jztey.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 一、 说明会类型 本次说明会以网络互动形式召开，公司将针对 2025 年第三季度的经营成果、业绩 亮点、"三新两化"战略实施进展等具体情况与投资者进行互动交流，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、 说明 ...

证券代码：600998 证券简称：九州通 公告编号：临 2025-076 九州通医药集团股份有限公司（以下简称"公司"或"九州通"）子公司北 京京丰制药集团（以下简称"京丰制药"）的下属子公司汇禹远和（海南）药业 有限公司（以下简称"汇禹远和"）于 2025 年 10 月 24 日收到国家药品监督管 理局核准签发的盐酸多巴胺注射液《药品补充申请批准通知书》，批准盐酸多巴 胺注射液（2.5ml:50mg）的上市许可持有人变更为汇禹远和。现将相关情况公告 如下： 一、药品补充申请批准通知书主要信息 药品名称：盐酸多巴胺注射液 剂型：注射剂 规格：2.5ml:50mg 注册分类：化学药品 九州通医药集团股份有限公司 关于获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通知书编号：2025B04915 原药品批准文号：国药准字 H20243909 九州通积极拓展医药工业自产及OEM业务，持续增品种、提品质，打造具 有市场竞争力的自有产品集群，助力"新产品"战略落地。2025年前三季度，公司 医药工业自 ...

证券代码：600998 证券简称：九州通 公告编号：临 2025-074 九州通医药集团股份有限公司 关于增加经营范围暨修订《公司章程》的公告 | 原条款 | 修订后条款 | | --- | --- | | 第十五条 | 第十五条 | | 经公司登记机关核准，公司经营 | 经公司登记机关核准，公司经营范围是： | | 范围是： | 许可项目：药品批发；危险化学品经营 一 | | 许可项目：药品批发；危险化学 | 般项目：第一类医疗器械销售 地产中草药 | | 品经营 一般项目：第一类 | （不含中药饮片）购销，装卸搬运、普通货物仓 | | 医疗器械销售 地产中草药 | 储服务（不含危险化学品等需许可审批的项目）、 | | （不含中药饮片）购销。（除许可 | 餐饮服务、业务培训（不含教育培训、职业技能 | | 业务外，可自主依法经营法律法 | 培训等需取得许可的培训）、会议及展览服务、 | | 规非禁止或限制的项目） | 企业管理、物业管理、法律咨询（不含依法须律 | | | 师事务所执业许可的业务）、健康咨询服务（不 | 1 | | 含诊疗服务）、远程健康管理服务、市场营销策 | | --- | --- | ...

九州通公告，第三季度营收为382.2亿元，同比增长5.41%；净利润为5.3亿元，同比增长8.46%。前三季 度营收为1193.27亿元，同比增长5.20%；净利润为19.75亿元，同比增长16.46%。 ...

九州通公告，子公司北京京丰制药集团下属子公司汇禹远和（海南）药业有限公司于2025年10月24日收 到国家药品监督管理局核准签发的盐酸多巴胺注射液《药品补充申请批准通知书》，批准盐酸多巴胺注 射液（2.5ml:50mg）的上市许可持有人变更为汇禹远和。该药品主要用于心肌梗死、创伤等引起的休克 综合征，以及心功能不全。2024年盐酸多巴胺注射液在医院的销售额达1.75亿元。 ...

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - The slow resumption of tin mines in Myanmar and the easing of Sino-US economic and trade negotiations support tin prices. The expectation of future interest rate cuts and the halt of balance - sheet reduction by the Fed, along with the initial agreement in Sino - US economic and trade negotiations, suggest that the resumption of tin mines in Myanmar may not change the tight supply - demand situation. The Shanghai tin price is expected to be cautiously bullish. Investors are advised to build long positions after price pullbacks, paying attention to support and resistance levels [3]. - The negative basis and monthly spread of Shanghai tin are due to high tin prices suppressing downstream demand with only rigid procurement. Given the Fed's future policies and the slow resumption of tin mines in Myanmar, investors are advised to focus on short - term, light - position, low - buying arbitrage opportunities for the Shanghai tin basis. For LME tin, the positive (0 - 3) and (3 - 15) contract spreads are in a reasonable range, and it is recommended to temporarily wait and see for arbitrage opportunities [9][10]. 3. Summary by Directory 3.1 First Part: Spread and Inventory Situation - Shanghai tin basis is negative and at a relatively low level, and the monthly spread is negative and basically within a reasonable range. LME tin (0 - 3) and (3 - 15) contract spreads are positive and in a reasonable range, and the Shanghai - London tin price ratio is at the 50% quantile of the past five years [9][10]. - The inventory of refined tin on the Shanghai Futures Exchange decreased compared to last week; the social inventory of tin ingots in China decreased compared to last week; the inventory of refined tin on the London Metal Exchange increased compared to last week; the total inventory of refined tin at home and abroad decreased compared to last week [12]. 3.2 Second Part: Mid - upstream Supply Situation - The daily processing fee of domestic tin concentrates is oscillating downward, indicating a tight supply expectation of domestic tin mines. The production (import) volume of domestic tin mines in October increased (increased) month - on - month. The production volume of recycled tin in China in October may increase month - on - month [19][21][24]. - The capacity utilization rate of refined tin in China increased compared to last week. The production (inventory) volume of refined tin in China in October increased (decreased) month - on - month, and the import volume may increase month - on - month [26][28][29]. 3.3 Third Part: Downstream Demand Situation - The daily processing fee of photovoltaic solder strips decreased month - on - month, which may lead to an increase in the capacity utilization rate (inventory) of tin solder in China in October. The import (export) volume of solder strips in China in October may decrease (decrease) month - on - month [35][38]. - The production volume of tin - plated sheets in China in October may increase month - on - month, while the import and export volumes may decrease month - on - month. The capacity utilization rate of lead - acid batteries in China increased compared to last week [41][43][46].

Group 1 - A new company, Henan Jiuzhoutong Medical Equipment Co., Ltd., has been established with a registered capital of 10 million RMB [1] - The legal representative of the company is Li Wa [1] - The business scope includes the sale of Class I and Class II medical devices, as well as the rental of Class I medical equipment [1] Group 2 - The company is jointly owned by Jiuzhoutong Medical Equipment Group Co., Ltd. and Henan Beijia Enterprise Management Consulting Co., Ltd. [1]

Market Overview - The pharmaceutical commercial sector increased by 0.32% compared to the previous trading day, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance - Jianfa Zhixin (301584) closed at 39.29, up 10.18% with a trading volume of 315,400 shares and a transaction value of 1.142 billion [1] - Run Da Medical (603108) closed at 15.30, up 3.66% with a trading volume of 180,900 shares and a transaction value of 274 million [1] - Other notable performers include Huaren Health (301408) up 2.28%, and Saili Medical (603716) up 1.98% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 6.1445 million from institutional investors, while retail investors saw a net inflow of 56.1279 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors increased their positions [2] Individual Stock Capital Flow - Run Da Medical saw a significant net outflow of 49.9539 million from institutional investors, indicating a bearish sentiment [3] - Conversely, Jiuzhoutong (866000) had a net inflow of 16.7641 million from institutional investors, suggesting positive interest [3] - Other stocks like Nanjing Medical (600713) and Huaren Health (301408) also showed varying degrees of net inflows and outflows from different investor categories [3]

Core Viewpoint - 九州通's stock performance on October 23 showed no change, with a trading volume of 116 million yuan, indicating a stable market position despite fluctuations in financing activities [1] Financing Summary - On October 23, 九州通 had a financing buy-in amount of 9.31 million yuan and a financing repayment of 16.99 million yuan, resulting in a net financing outflow of 7.68 million yuan [1] - The total financing and securities lending balance for 九州通 as of October 23 was 721 million yuan, with the financing balance at 714 million yuan, accounting for 2.83% of the circulating market value, which is below the 30th percentile of the past year [1] - In terms of securities lending, 九州通 repaid 181,700 shares and sold 11,000 shares on October 23, with a selling amount of 55,100 yuan, while the remaining securities lending volume was 1.37 million shares, with a balance of 6.88 million yuan, exceeding the 90th percentile of the past year [1] Business Overview - 九州通, established on March 9, 1999, and listed on November 2, 2010, is based in Wuhan, Hubei Province, and operates in six main business areas: digital pharmaceutical distribution and supply chain, general brand promotion, pharmaceutical manufacturing and OEM, retail and franchise, digital logistics and supply chain solutions, and healthcare and technology value-added services [1] - The revenue composition of 九州通's main business includes: distribution segment 95.94%, industrial segment 1.96%, retail segment 1.84%, healthcare segment 0.17%, and other segments 0.08% [1] Financial Performance - As of June 30, 九州通 reported a total of 41,700 shareholders, a decrease of 12.92% from the previous period, with an average of 120,824 circulating shares per shareholder, an increase of 14.84% [2] - For the first half of 2025, 九州通 achieved an operating income of 81.11 billion yuan, a year-on-year increase of 5.10%, and a net profit attributable to shareholders of 1.45 billion yuan, reflecting a year-on-year growth of 19.70% [2] Dividend Information - 九州通 has cumulatively distributed dividends of 5.27 billion yuan since its A-share listing, with 2.91 billion yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the seventh largest circulating shareholder of 九州通, holding 90.25 million shares, an increase of 8.74 million shares from the previous period [3]

Core Insights - The annual report released by Wuhan Enterprise Federation and Wuhan Entrepreneur Association highlights the significant growth and transformation of Wuhan's economy, with the total assets of the top 100 enterprises reaching 6.39 trillion yuan, a year-on-year increase of 10.1% [3][5]. Group 1: Enterprise Structure and Rankings - The number of private enterprises in the top 100 reached 50, surpassing state-owned enterprises for the first time, which numbered 48 [3][5]. - The top 20 enterprises are predominantly state-owned, holding 70% of the positions, indicating their continued influence in key sectors [3][5]. - China State Construction Engineering Corporation ranked first in the comprehensive top 100, followed by Dongfeng Motor Corporation and Zhuoer Zhili Group [13][15]. Group 2: Financial Performance - The revenue threshold for entering the top 100 was set at 4.738 billion yuan, slightly higher than the previous year [7]. - Eight enterprises achieved "billion-level" revenue, while the number of "hundred-billion-level" enterprises increased from 53 to 56 [7]. - The total profit of the comprehensive top 100 enterprises reached 69.957 billion yuan, with 83 enterprises reporting profits and 46 showing positive profit growth [7]. Group 3: Innovation and R&D - A total of 74 enterprises in the top 100 invested in R&D, with total R&D expenditure amounting to 60.424 billion yuan [9][11]. - Private enterprises showed a significant increase in R&D investment, growing by 54.26% year-on-year, outpacing revenue and profit growth [11]. - The number of enterprises with overseas revenue reached 40, generating a total of 189.224 billion yuan from international markets, a year-on-year increase of 57.76% [11]. Group 4: Industry Trends - The structure of the top enterprises is shifting, with an increase in service sector companies and a decrease in construction firms, reflecting a transition from investment-driven to innovation-driven growth [13]. - The report indicates a strong performance in sectors such as "optical, chip, screen, terminal, and network" and logistics, particularly among large state-owned enterprises [9].